Lassa virus diversity and feasibility for universal prophylactic vaccine [version 1; peer review: 3 approved]

Lassa virus diversity and feasibility for universal prophylactic vaccine [version 1; peer review: 3 approved]

Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity...

Full description

Saved in:
Bibliographic Details
Published in:F1000 research Vol. 8; p. 134
Main Authors: Lukashevich, Igor S, Paessler, Slobodan, de la Torre, Juan Carlos
Format: Journal Article
Language:English
Published: England Faculty of 1000 Ltd 2019
F1000 Research Limited
F1000 Research Ltd
Subjects:
Biodiversity
Candidates
Drug development
Fatalities
Fever
Food contamination & poisoning
Genetic diversity
Genomes
Infections
Lassa fever
Morbidity
Mortality
Pediatrics
Phylogenetics
Public health
Review
RNA polymerase
Severe acute respiratory syndrome
Tropical diseases
Vaccine development
Vaccines
Liberia
Togo
Mali
United States > US
West Africa
Ivory Coast
Nigeria
vaccine development
Lassa virus
Lassa fever
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO's TPP for an LASV vaccine.
AbstractList Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO’s TPP for an LASV vaccine.
Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, , which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO's TPP for an LASV vaccine.
Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis , which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO’s TPP for an LASV vaccine.
Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis, which is widely spread in sub-Saharan Africa. LASV infection of humans can cause Lassa fever (LF), a disease associated with high morbidity and significant mortality. Recent evidence indicates an LASV expansion outside its traditional endemic areas. In 2017, the World Health Organization (WHO) included LASV in top-priority pathogens and released a Target Product Profile (TPP) for vaccine development. Likewise, in 2018, the US Food and Drug Administration added LF to a priority review voucher program to encourage the development of preventive and therapeutics measures. In this article, we review recent progress in LASV vaccine research and development with a focus on the impact of LASV genetic and biological diversity on the design and development of vaccine candidates meeting the WHO's TPP for an LASV vaccine.
Author de la Torre, Juan Carlos
Paessler, Slobodan
Lukashevich, Igor S
Author_xml – sequence: 1
  givenname: Igor S
  orcidid: 0000-0001-6523-5116
  surname: Lukashevich
  fullname: Lukashevich, Igor S
  email: igor.lukashevich@louisville.edu
  organization: Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, 40292, USA
– sequence: 2
  givenname: Slobodan
  surname: Paessler
  fullname: Paessler, Slobodan
  organization: Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, 77555, USA
– sequence: 3
  givenname: Juan Carlos
  surname: de la Torre
  fullname: de la Torre, Juan Carlos
  organization: Department of Immunology and Microbiology IMM-6, The Scripps Research Institute, La Jolla, CA, 92037, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30774934$$D View this record in MEDLINE/PubMed
BookMark eNp9kktvEzEUhS1UREvoX6gssWGTYI9n7HGRkKqKR6VIbGCFkHVnfN04mowHOzMo_x4nKaVhwcqvcz7de31ekrM-9EjIFWcLXsi6fus4YyxiQojtasGlrvWCPyMXBSvlnJesOHuyPyeXKa2zgWktZKFekHPBlCq1KC_IZgkpAZ18HBO1fsKY_HZHobfUISTf-G5_diHSsT88Q0eHGIbVroN261s6Qdv6Hun3gzf0lL-jA2KkESePv66poDBkx4T2xyvy3EGX8PJhnZFvHz98vf08X375dHd7s5y3pSr53KqKN66ulONVpWXDgLuiLiphsWkaZOgUCi1rwayV0irRMJXnohVaK5pKiBm5O3JtgLUZot9A3JkA3hwuQrw3EHPxHRotoJCAopDalQwq7eo8TqWVFDWUJcus90fWMDYbtC322wjdCfT0pfcrcx8mI0WltC4z4M0DIIafI6at2fjUYtdBj2FMpuC14HUltcrS1_9I12GMfR7VXiV1_ufc9YzIo6qNIaWI7rEYzswhIOYkIOYQEMOz8eppK4-2P3HIguujwEE7dtvdnmL-Yv5P_w1VOM4n
CitedBy_id crossref_primary_10_1089_vbz_2020_2661
crossref_primary_10_1186_s40814_020_00567_4
crossref_primary_10_3390_v13030484
crossref_primary_10_1128_JVI_01399_21
crossref_primary_10_3390_v13040703
crossref_primary_10_3390_nu15194097
crossref_primary_10_36233_0372_9311_113
crossref_primary_10_1038_s41598_022_26045_w
crossref_primary_10_3390_v12090907
crossref_primary_10_1080_07391102_2021_1896387
crossref_primary_10_1038_s41598_020_72539_w
crossref_primary_10_1038_s41467_022_33112_3
crossref_primary_10_1080_22221751_2023_2219350
crossref_primary_10_1128_jvi_01688_22
crossref_primary_10_1016_j_drudis_2022_04_008
crossref_primary_10_3390_v13020214
crossref_primary_10_3390_v12070772
crossref_primary_10_3390_v15010146
crossref_primary_10_3390_biomedicines10102433
crossref_primary_10_3390_v12040386
crossref_primary_10_1080_21505594_2021_2000290
crossref_primary_10_3390_v16040635
crossref_primary_10_3390_vaccines10101668
Cites_doi 10.1038/ncomms11544
10.1128/JVI.77.3.1727-1737.2003
10.1016/S0140-6736(79)90659-7
10.1016/j.cell.2015.07.020
10.1128/JVI.74.15.6992-7004.2000
10.1007/978-3-642-71726-0_2
10.1016/S0140-6736(87)90767-7
10.3389/fmicb.2015.01037
10.1038/srep25280
10.2105/AJPH.2017.304186
10.1056/NEJMoa1502924
10.3389/fpubh.2018.00232
10.1038/s41467-018-06741-w
10.3201/eid2403.171905
10.1016/j.virol.2006.01.026
10.1016/j.antiviral.2007.11.003
10.1586/14760584.3.2.189
10.1371/journal.pntd.0003736
10.1093/infdis/jit004
10.1016/j.tim.2018.08.008
10.1038/nature14428
10.1111/j.1863-2378.2012.01469.x
10.3390/pathogens7040084
10.1128/JVI.03035-13
10.1016/S1473-3099(18)30121-X
10.1128/JVI.01948-08
10.1126/science.185.4147.263
10.4269/ajtmh.1970.19.695
10.1016/0168-1702(88)90033-0
10.1016/S0140-6736(15)61117-5
10.1016/S1473-3099(18)30179-8
10.1016/j.virol.2005.01.019
10.1016/0042-6822(92)90514-P
10.1016/j.coviro.2013.04.007
10.1177/0300985816677153
10.1128/JVI.78.10.5458-5465.2004
10.1093/clinids/11.Supplement_4.S783
10.4269/ajtmh.1970.19.670
10.4172/2157-7560.1000160
10.1016/j.vaccine.2011.12.134
10.1128/JVI.02876-06
10.3201/eid1512.090864
10.1371/journal.pntd.0000388
10.1016/j.antiviral.2011.07.015
10.1016/j.virol.2005.12.001
10.2174/138920206778948673
10.1128/JVI.00896-06
10.1186/1743-422X-8-205
10.1371/journal.pntd.0006187
10.4269/ajtmh.1970.19.692
10.1007/978-3-642-71726-0_3
10.1007/BF02122438
10.1016/j.virol.2003.12.013
10.1128/JVI.02948-15
10.1016/S0140-6736(18)30560-9
10.1038/srep21977
10.4161/hv.7.6.15198
10.1080/21645515.2017.1306615
10.1371/journal.pntd.0006971
10.1016/j.actbio.2018.08.033
10.1089/15303660160025912
10.1038/s41541-018-0049-5
10.1111/2041-210X.12549
10.1016/j.vaccine.2017.12.046
10.1016/B978-1-78548-277-9.50011-5
10.1126/science.351.6268.16
10.1038/nri.2016.138
10.3390/v4102031
10.1093/infdis/jiv316
10.1093/infdis/jix201
10.1016/0042-6822(89)90525-4
10.1371/journal.pntd.0001839
10.1016/j.antiviral.2016.08.012
10.4269/ajtmh.1996.55.661
10.1128/mBio.01896-18
10.1056/NEJM198601023140104
10.3201/eid0605.000504
10.1128/JVI.02230-17
10.4269/ajtmh.1986.35.401
10.1016/j.vaccine.2007.02.038
10.1016/j.virol.2014.12.011
10.1371/journal.pone.0122839
10.1586/erv.12.139
10.1080/20477724.2017.1369643
10.1093/infdis/155.3.456
10.1016/0035-9203(85)90386-4
10.4049/jimmunol.180.5.3113
10.1111/j.1365-294X.2012.05663.x
10.1056/NEJMoa1804498
10.1371/journal.pmed.0020183
10.1128/JVI.01190-17
10.3390/v4112766
10.4049/jimmunol.170.6.2797
10.1126/science.359.6381.1201
10.1016/j.vaccine.2010.11.079
10.1093/infdis/155.3.437
10.1080/14787210.2018.1512856
10.1073/pnas.0900088106
10.1016/j.cell.2016.06.029
10.1136/bmj.1.6073.1399
10.1093/infdis/155.3.445
10.1186/1743-422X-10-52
10.1007/s00705-015-2418-y
10.1371/journal.ppat.1006073
10.1128/IAI.37.2.771-778.1982
10.3201/eid2204.150155
10.1128/JVI.79.22.13934-13942.2005
10.1128/JVI.75.23.11677-11685.2001
10.1126/scitranslmed.aaj1701
10.3201/eid1710.10452
10.1128/JCM.01891-10
10.1128/JVI.74.5.2186-2192.2000
10.1080/14760584.2016.1184575
10.1136/bmj.327.7426.1271
10.1080/21645515.2017.1356500
10.1016/j.vaccine.2008.07.057
10.1186/s13071-018-2991-5
10.1128/JVI.74.15.6777-6783.2000
10.3201/eid2104.141469
10.1016/S0140-6736(16)32621-6
10.1016/S1473-3099(15)70043-5
10.1128/JVI.03441-13
ContentType Journal Article
Copyright Copyright: © 2019 Lukashevich IS et al.
Copyright: © 2019 Lukashevich IS et al. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright: © 2019 Lukashevich IS et al. 2019
Copyright_xml – notice: Copyright: © 2019 Lukashevich IS et al.
– notice: Copyright: © 2019 Lukashevich IS et al. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright: © 2019 Lukashevich IS et al. 2019
DBID C-E
CH4
NPM
AAYXX
CITATION
3V.
7X7
7XB
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M2P
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.12688/f1000research.16989.1
DatabaseName F1000Research
Faculty of 1000
PubMed
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Science Database
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
PubMed

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Women's Studies
Public Health
EISSN 2046-1402
ExternalDocumentID oai_doaj_org_article_93a26ae3269f40a59f8698797638a440
10_12688_f1000research_16989_1
30774934
Genre Journal Article
Review
Research Support, N.I.H., Extramural
GeographicLocations Liberia
Togo
Mali
United States--US
West Africa
Ivory Coast
Nigeria
GeographicLocations_xml – name: West Africa
– name: Ivory Coast
– name: Togo
– name: Nigeria
– name: Mali
– name: Liberia
– name: United States--US
GrantInformation_xml – fundername: National Institute of Allergy and Infectious Diseases
  grantid: R01AI093450
– fundername: National Institute of Allergy and Infectious Diseases
  grantid: R56AI135770
– fundername: NIAID NIH HHS
  grantid: R56 AI135770
– fundername: NIAID NIH HHS
  grantid: R01 AI093450
GroupedDBID 3V.
53G
5VS
7X7
88I
8FE
8FH
8FI
8FJ
ABUWG
ACGOD
ACPRK
ADACO
ADBBV
ADRAZ
AFKRA
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BAWUL
BBAFP
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C-E
CH4
DIK
DWQXO
FRP
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HYE
KQ8
LK8
M2P
M7P
OK1
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
PROAC
RPM
AAFWJ
ALIPV
AOIJS
CCPQU
HMCUK
M48
M~E
NPM
PGMZT
UKHRP
W2D
AAYXX
CITATION
7XB
8FK
COVID
K9.
Q9U
7X8
5PM
ID FETCH-LOGICAL-c4741-d751bf857f15596b0a1f28253debbbe0ef7e396830dd66d73b0726897edd3b533
IEDL.DBID RPM
ISSN 2046-1402
IngestDate Tue Oct 22 15:11:46 EDT 2024
Tue Sep 17 21:26:35 EDT 2024
Fri Aug 16 07:46:56 EDT 2024
Wed Oct 16 14:21:26 EDT 2024
Fri Aug 23 03:24:45 EDT 2024
Sat Sep 28 08:28:02 EDT 2024
Mon Jan 18 12:18:50 EST 2021
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords vaccine development
Lassa virus
Lassa fever
Language English
License http://creativecommons.org/licenses/by/4.0/: This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4741-d751bf857f15596b0a1f28253debbbe0ef7e396830dd66d73b0726897edd3b533
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
No competing interests were disclosed.
ORCID 0000-0001-6523-5116
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357994/
PMID 30774934
PQID 2186998968
PQPubID 2045578
ParticipantIDs doaj_primary_oai_doaj_org_article_93a26ae3269f40a59f8698797638a440
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6357994
proquest_miscellaneous_2183185697
proquest_journals_2186998968
crossref_primary_10_12688_f1000research_16989_1
pubmed_primary_30774934
faculty1000_research_10_12688_f1000research_16989_1
ProviderPackageCode C-E
CH4
PublicationCentury 2000
PublicationDate 2019-00-00
PublicationDateYYYYMMDD 2019-01-01
PublicationDate_xml – year: 2019
  text: 2019-00-00
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
– name: London, UK
PublicationTitle F1000 research
PublicationTitleAlternate F1000Res
PublicationYear 2019
Publisher Faculty of 1000 Ltd
F1000 Research Limited
F1000 Research Ltd
Publisher_xml – name: Faculty of 1000 Ltd
– name: F1000 Research Limited
– name: F1000 Research Ltd
References S Plotkin (ref-113) 2017; 13
D Safronetz (ref-55) 2013; 207
J McCormick (ref-25) 1986; 314
M Bowen (ref-40) 2000; 74
A Schildknecht (ref-89) 2008; 180
E Keane (ref-58) 1977; 1
J Robinson (ref-84) 2016; 7
K Ramsauer (ref-114) 2015; 15
P Pushko (ref-102) 2001; 75
(ref-35) 2017
I Lukashevich (ref-86) 1992; 188
S Whitmer (ref-43) 2018; 24
T Geisbert (ref-97) 2005; 2
D Matassov (ref-128) 2018; 92
S Günther (ref-14) 2009; 15
C Peters (ref-49) 1987; 134
J Cohen (ref-104) 2016; 351
K Johnson (ref-27) 1987; 155
D Asogun (ref-67) 2012; 6
J Zapata (ref-106) 2014; 88
T Monath (ref-5) 1974; 185
M Kiley (ref-98) 1979; 2
S Gryseels (ref-16) 2015; 476
J McCormick (ref-80) 1999
J McCormick (ref-79) 1986; 175
(ref-115) 2018
T Abreu-Mota (ref-134) 2018; 9
J Frame (ref-1) 1970; 19
M Meyer (ref-124) 2019; 27
L Hensley (ref-53) 2011; 8
J McCormick (ref-62) 1986; 35
R Cross (ref-83) 2016; 133
G Akpede (ref-29) 2018; 16
D Auperin (ref-95) 1988; 9
J Richmond (ref-22) 2003; 327
S Khan (ref-132) 2008; 78
J Prescott (ref-54) 2017; 17
S Fisher-Hoch (ref-74) 2000; 74
J ter Meulen (ref-81) 2000; 74
R Carrion (ref-46) 2007; 25
N Shehu (ref-65) 2018; 6
S Mahanty (ref-61) 2003; 170
W Metzger (ref-121) 2018; 391
O Oloniniyi (ref-69) 2018; 12
J McCormick (ref-28) 2002; 262
A Henao-Restrepo (ref-120) 2015; 386
A Demby (ref-8) 2001; 1
R Carrion (ref-66) 2007; 81
J Meulen (ref-82) 2004; 321
J Botten (ref-85) 2006; 80
T Bell (ref-47) 2016; 54
A Ambrosio (ref-131) 2011; 7
(ref-33) 2017
E Fichet-Calvet (ref-9) 2016; 6
S Emonet (ref-112) 2009; 106
J Ter Meulen (ref-70) 1996; 55
P Jahrling (ref-51) 1985; 79
K Cashman (ref-110) 2017; 13
S Baize (ref-52) 2009; 83
R Gibb (ref-11) 2017; 111
I Lukashevich (ref-88) 2016; 15
K Siddle (ref-68) 2018; 379
X Jiang (ref-101) 2011; 29
K Andersen (ref-38) 2015; 162
J Troup (ref-2) 1970; 19
D Falzarano (ref-24) 2013; 3
D Ehichioya (ref-37) 2011; 49
A Olayemi (ref-17) 2016; 22
A Lalis (ref-6) 2018
N Yun (ref-76) 2012; 4
I Lukashevich (ref-87) 2005; 79
J Manning (ref-39) 2015; 6
J Frame (ref-60) 1989; 11 Suppl 4
J McCormick (ref-7) 1987; 134
M Garbutt (ref-96) 2004; 78
K Cashman (ref-73) 2018; 9
(ref-129) 2018
N Irwin (ref-19) 2012; 21
S Fisher-Hoch (ref-75) 2014; 3
J Zapata (ref-91) 2011; 92
M Iwasaki (ref-111) 2018
J Zapata (ref-93) 2018; 7
J Lee (ref-116) 2018; 80
N Sogoba (ref-20) 2012; 59 Suppl 2
(ref-32) 2018; 18
S Isa (ref-64) 2013; 13
M Rodriguez-Carreno (ref-118) 2005; 335
M Buba (ref-30) 2018; 108
N Yozwiak (ref-133) 2016; 166
I Lukashevich (ref-105) 2008; 26
R Speir (ref-4) 1970; 19
J Clegg (ref-50) 1987; 330
(ref-94) 2017
P Okokhere (ref-56) 2018; 18
(ref-34) 2018
M Russier (ref-130) 2012; 4
X Carnec (ref-99) 2018; 92
D Redding (ref-10) 2016; 7
J McCormick (ref-59) 1987; 155
C Mire (ref-127) 2015; 520
D Safronetz (ref-48) 2015; 9
M Wang (ref-103) 2018; 36
D Clarke (ref-125) 2014; 88
N Yun (ref-72) 2015; 90
I Lukashevich (ref-63) 2003; 77
P Jahrling (ref-45) 1982; 37
J Zapata (ref-92) 2013; 10
S Gryseels (ref-12) 2017; 13
S Günther (ref-42) 2000; 6
I Lukashevich (ref-36) 2006; 7
H Hallam (ref-77) 2018; 3
J Kelvey (ref-117) 2018
S Agnandji (ref-122) 2016; 374
E Fichet-Calvet (ref-23) 2009; 3
H Morrison (ref-109) 1989; 171
J Beier (ref-57) 2015; 10
R Carrion (ref-107) 2012; 3
A Henao-Restrepo (ref-119) 2017; 389
D Matassov (ref-126) 2015; 212 Suppl 2
L Roberts (ref-31) 2018; 359
A Huttner (ref-123) 2017; 9
A Olayemi (ref-18) 2018; 11
T Leski (ref-41) 2015; 21
A Ishii (ref-15) 2011; 17
P Bredenbeek (ref-100) 2006; 345
H Wulff (ref-13) 1977; 55
S Emonet (ref-90) 2006; 350
I Lukashevich (ref-44) 2013; 12
J McCormick (ref-26) 1987; 155
M Goicochea (ref-108) 2012; 30
A Olayemi (ref-21) 2016; 6
E Mateer (ref-71) 2018; 12
A McElroy (ref-78) 2017; 215
S Radoshitzky (ref-3) 2015; 160
References_xml – volume: 7
  year: 2016
  ident: ref-84
  article-title: Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.
  publication-title: Nat Commun.
  doi: 10.1038/ncomms11544
  contributor:
    fullname: J Robinson
– volume: 77
  start-page: 1727-37
  year: 2003
  ident: ref-63
  article-title: Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation.
  publication-title: J Virol.
  doi: 10.1128/JVI.77.3.1727-1737.2003
  contributor:
    fullname: I Lukashevich
– volume: 2
  start-page: 738
  year: 1979
  ident: ref-98
  article-title: Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus.
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(79)90659-7
  contributor:
    fullname: M Kiley
– volume: 162
  start-page: 738-50
  year: 2015
  ident: ref-38
  article-title: Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus.
  publication-title: Cell.
  doi: 10.1016/j.cell.2015.07.020
  contributor:
    fullname: K Andersen
– volume: 74
  start-page: 6992-7004
  year: 2000
  ident: ref-40
  article-title: Genetic diversity among Lassa virus strains.
  publication-title: J Virol.
  doi: 10.1128/JVI.74.15.6992-7004.2000
  contributor:
    fullname: M Bowen
– volume: 134
  start-page: 5-68
  year: 1987
  ident: ref-49
  article-title: Experimental studies of arenaviral hemorrhagic fevers.
  publication-title: Curr Top Microbiol Immunol.
  doi: 10.1007/978-3-642-71726-0_2
  contributor:
    fullname: C Peters
– volume: 330
  start-page: 186-8
  year: 1987
  ident: ref-50
  article-title: Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(87)90767-7
  contributor:
    fullname: J Clegg
– volume: 6
  start-page: 1037
  year: 2015
  ident: ref-39
  article-title: Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage.
  publication-title: Front Microbiol.
  doi: 10.3389/fmicb.2015.01037
  contributor:
    fullname: J Manning
– volume: 6
  start-page: 25280
  year: 2016
  ident: ref-21
  article-title: New Hosts of The Lassa Virus.
  publication-title: Sci Rep.
  doi: 10.1038/srep25280
  contributor:
    fullname: A Olayemi
– volume: 108
  start-page: 262-264
  year: 2018
  ident: ref-30
  article-title: Mortality Among Confirmed Lassa Fever Cases During the 2015-2016 Outbreak in Nigeria.
  publication-title: Am J Public Health.
  doi: 10.2105/AJPH.2017.304186
  contributor:
    fullname: M Buba
– volume: 374
  start-page: 1647-60
  year: 2016
  ident: ref-122
  article-title: Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1502924
  contributor:
    fullname: S Agnandji
– volume: 6
  start-page: 232
  year: 2018
  ident: ref-65
  article-title: Lassa Fever 2016 Outbreak in Plateau State, Nigeria-The Changing Epidemiology and Clinical Presentation.
  publication-title: Front Public Health.
  doi: 10.3389/fpubh.2018.00232
  contributor:
    fullname: N Shehu
– volume: 9
  start-page: 4223
  year: 2018
  ident: ref-134
  article-title: Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
  publication-title: Nat Commun.
  doi: 10.1038/s41467-018-06741-w
  contributor:
    fullname: T Abreu-Mota
– year: 2017
  ident: ref-35
  article-title: Nigeria - Lassa Fever
– volume: 24
  start-page: 599-602
  year: 2018
  ident: ref-43
  article-title: New Lineage of Lassa Virus, Togo, 2016.
  publication-title: Emerging Infect Dis.
  doi: 10.3201/eid2403.171905
  contributor:
    fullname: S Whitmer
– volume: 350
  start-page: 251-7
  year: 2006
  ident: ref-90
  article-title: Phylogeny and evolution of old world arenaviruses.
  publication-title: Virology.
  doi: 10.1016/j.virol.2006.01.026
  contributor:
    fullname: S Emonet
– volume: 78
  start-page: 103-15
  year: 2008
  ident: ref-132
  article-title: New opportunities for field research on the pathogenesis and treatment of Lassa fever.
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2007.11.003
  contributor:
    fullname: S Khan
– volume: 3
  start-page: 189-97
  year: 2014
  ident: ref-75
  article-title: Lassa fever vaccine.
  publication-title: Expert Rev Vaccines.
  doi: 10.1586/14760584.3.2.189
  contributor:
    fullname: S Fisher-Hoch
– volume: 9
  start-page: e0003736
  year: 2015
  ident: ref-48
  article-title: A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
  publication-title: PLoS Negl Trop Dis.
  doi: 10.1371/journal.pntd.0003736
  contributor:
    fullname: D Safronetz
– volume: 207
  start-page: 1316-27
  year: 2013
  ident: ref-55
  article-title: A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques.
  publication-title: J Infect Dis.
  doi: 10.1093/infdis/jit004
  contributor:
    fullname: D Safronetz
– volume: 262
  start-page: 75-109
  year: 2002
  ident: ref-28
  article-title: Lassa fever.
  publication-title: Curr Top Microbiol Immunol.
  contributor:
    fullname: J McCormick
– volume: 27
  start-page: 8-16
  year: 2019
  ident: ref-124
  article-title: Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?
  publication-title: Trends Microbiol.
  doi: 10.1016/j.tim.2018.08.008
  contributor:
    fullname: M Meyer
– volume: 520
  start-page: 688-91
  year: 2015
  ident: ref-127
  article-title: Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
  publication-title: Nature.
  doi: 10.1038/nature14428
  contributor:
    fullname: C Mire
– volume: 59 Suppl 2
  start-page: 43-7
  year: 2012
  ident: ref-20
  article-title: Lassa fever in West Africa: evidence for an expanded region of endemicity.
  publication-title: Zoonoses Public Health.
  doi: 10.1111/j.1863-2378.2012.01469.x
  contributor:
    fullname: N Sogoba
– volume: 7
  year: 2018
  ident: ref-93
  article-title: Improving the Breadth of the Host's Immune Response to Lassa Virus.
  publication-title: Pathogens.
  doi: 10.3390/pathogens7040084
  contributor:
    fullname: J Zapata
– volume: 88
  start-page: 3058-66
  year: 2014
  ident: ref-106
  article-title: Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate.
  publication-title: J Virol.
  doi: 10.1128/JVI.03035-13
  contributor:
    fullname: J Zapata
– volume: 18
  start-page: 684-95
  year: 2018
  ident: ref-56
  article-title: Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.
  publication-title: Lancet Infect Dis.
  doi: 10.1016/S1473-3099(18)30121-X
  contributor:
    fullname: P Okokhere
– volume: 83
  start-page: 5890-903
  year: 2009
  ident: ref-52
  article-title: Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.
  publication-title: J Virol.
  doi: 10.1128/JVI.01948-08
  contributor:
    fullname: S Baize
– volume: 185
  start-page: 263-5
  year: 1974
  ident: ref-5
  article-title: Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone.
  publication-title: Science.
  doi: 10.1126/science.185.4147.263
  contributor:
    fullname: T Monath
– volume: 19
  start-page: 695-6
  year: 1970
  ident: ref-2
  article-title: An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report.
  publication-title: Am J Trop Med Hyg.
  doi: 10.4269/ajtmh.1970.19.695
  contributor:
    fullname: J Troup
– volume: 9
  start-page: 233-48
  year: 1988
  ident: ref-95
  article-title: Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection.
  publication-title: Virus Res.
  doi: 10.1016/0168-1702(88)90033-0
  contributor:
    fullname: D Auperin
– volume: 386
  start-page: 857-66
  year: 2015
  ident: ref-120
  article-title: Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(15)61117-5
  contributor:
    fullname: A Henao-Restrepo
– volume: 18
  start-page: 357
  year: 2018
  ident: ref-32
  article-title: Lassa fever and global health security.
  publication-title: Lancet Infect Dis.
  doi: 10.1016/S1473-3099(18)30179-8
– volume: 335
  start-page: 87-98
  year: 2005
  ident: ref-118
  article-title: Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
  publication-title: Virology.
  doi: 10.1016/j.virol.2005.01.019
  contributor:
    fullname: M Rodriguez-Carreno
– volume: 188
  start-page: 600-5
  year: 1992
  ident: ref-86
  article-title: Generation of reassortants between African arenaviruses.
  publication-title: Virology.
  doi: 10.1016/0042-6822(92)90514-P
  contributor:
    fullname: I Lukashevich
– volume: 3
  start-page: 343-51
  year: 2013
  ident: ref-24
  article-title: Vaccines for viral hemorrhagic fevers--progress and shortcomings.
  publication-title: Curr Opin Virol.
  doi: 10.1016/j.coviro.2013.04.007
  contributor:
    fullname: D Falzarano
– volume: 54
  start-page: 549-62
  year: 2016
  ident: ref-47
  article-title: Temporal Progression of Lesions in Guinea Pigs Infected With Lassa Virus.
  publication-title: Vet Pathol.
  doi: 10.1177/0300985816677153
  contributor:
    fullname: T Bell
– volume: 78
  start-page: 5458-65
  year: 2004
  ident: ref-96
  article-title: Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.
  publication-title: J Virol.
  doi: 10.1128/JVI.78.10.5458-5465.2004
  contributor:
    fullname: M Garbutt
– volume: 11 Suppl 4
  start-page: S783-S789
  year: 1989
  ident: ref-60
  article-title: Clinical features of Lassa fever in Liberia.
  publication-title: Rev Infect Dis.
  doi: 10.1093/clinids/11.Supplement_4.S783
  contributor:
    fullname: J Frame
– volume: 13
  start-page: 3-7
  year: 2013
  ident: ref-64
  article-title: Epidemiological and clinical description of Lassa fever in Jos, Nigeria.
  publication-title: High Med Res J.
  contributor:
    fullname: S Isa
– volume: 19
  start-page: 670-6
  year: 1970
  ident: ref-1
  article-title: Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.
  publication-title: Am J Trop Med Hyg.
  doi: 10.4269/ajtmh.1970.19.670
  contributor:
    fullname: J Frame
– volume: 3
  year: 2012
  ident: ref-107
  article-title: Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.
  publication-title: J Vaccines Vaccin.
  doi: 10.4172/2157-7560.1000160
  contributor:
    fullname: R Carrion
– volume: 30
  start-page: 1445-52
  year: 2012
  ident: ref-108
  article-title: Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model.
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2011.12.134
  contributor:
    fullname: M Goicochea
– volume: 55
  start-page: 441-4
  year: 1977
  ident: ref-13
  article-title: Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa.
  publication-title: Bull World Health Organ.
  contributor:
    fullname: H Wulff
– year: 2017
  ident: ref-33
  article-title: Annual review of diseases prioritized under the Research and Development Blueprint
– volume: 81
  start-page: 6482-90
  year: 2007
  ident: ref-66
  article-title: Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues.
  publication-title: J Virol.
  doi: 10.1128/JVI.02876-06
  contributor:
    fullname: R Carrion
– volume: 15
  start-page: 2008-12
  year: 2009
  ident: ref-14
  article-title: Mopeia virus-related arenavirus in natal multimammate mice, Morogoro, Tanzania.
  publication-title: Emerg Infect Dis.
  doi: 10.3201/eid1512.090864
  contributor:
    fullname: S Günther
– volume: 3
  start-page: e388
  year: 2009
  ident: ref-23
  article-title: Risk Maps of Lassa Fever in West Africa.
  publication-title: PLoS Negl Trop Dis.
  doi: 10.1371/journal.pntd.0000388
  contributor:
    fullname: E Fichet-Calvet
– volume: 92
  start-page: 125-38
  year: 2011
  ident: ref-91
  article-title: Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever.
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2011.07.015
  contributor:
    fullname: J Zapata
– volume: 345
  start-page: 299-304
  year: 2006
  ident: ref-100
  article-title: A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
  publication-title: Virology.
  doi: 10.1016/j.virol.2005.12.001
  contributor:
    fullname: P Bredenbeek
– volume: 7
  start-page: 351-79
  year: 2006
  ident: ref-36
  article-title: Lassa Virus Genome.
  publication-title: Curr Genomics.
  doi: 10.2174/138920206778948673
  contributor:
    fullname: I Lukashevich
– volume: 80
  start-page: 8351-61
  year: 2006
  ident: ref-85
  article-title: Identification of protective Lassa virus epitopes that are restricted by HLA-A2.
  publication-title: J Virol.
  doi: 10.1128/JVI.00896-06
  contributor:
    fullname: J Botten
– volume: 8
  start-page: 205
  year: 2011
  ident: ref-53
  article-title: Pathogenesis of lassa fever in cynomolgus macaques.
  publication-title: Virol J.
  doi: 10.1186/1743-422X-8-205
  contributor:
    fullname: L Hensley
– volume: 12
  start-page: e0006187
  year: 2018
  ident: ref-71
  article-title: Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden.
  publication-title: PLoS Negl Trop Dis.
  doi: 10.1371/journal.pntd.0006187
  contributor:
    fullname: E Mateer
– volume: 19
  start-page: 692-4
  year: 1970
  ident: ref-4
  article-title: Lassa fever, a new virus disease of man from West Africa. IV. Electron microscopy of Vero cell cultures infected with Lassa virus.
  publication-title: Am J Trop Med Hyg.
  doi: 10.4269/ajtmh.1970.19.692
  contributor:
    fullname: R Speir
– volume: 134
  start-page: 69-78
  year: 1987
  ident: ref-7
  article-title: Epidemiology and control of Lassa fever.
  publication-title: Curr Top Microbiol Immunol.
  doi: 10.1007/978-3-642-71726-0_3
  contributor:
    fullname: J McCormick
– volume: 175
  start-page: 153-5
  year: 1986
  ident: ref-79
  article-title: Clinical, epidemiologic, and therapeutic aspects of Lassa fever.
  publication-title: Med Microbiol Immunol.
  doi: 10.1007/BF02122438
  contributor:
    fullname: J McCormick
– volume: 321
  start-page: 134-43
  year: 2004
  ident: ref-82
  article-title: Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones.
  publication-title: Virology.
  doi: 10.1016/j.virol.2003.12.013
  contributor:
    fullname: J Meulen
– volume: 90
  start-page: 2920-7
  year: 2015
  ident: ref-72
  article-title: Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection.
  publication-title: J Virol.
  doi: 10.1128/JVI.02948-15
  contributor:
    fullname: N Yun
– volume: 391
  start-page: 1021
  year: 2018
  ident: ref-121
  article-title: Questionable efficacy of the rVSV-ZEBOV Ebola vaccine.
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(18)30560-9
  contributor:
    fullname: W Metzger
– volume: 6
  year: 2016
  ident: ref-9
  article-title: Spatial and temporal evolution of Lassa virus in the natural host population in Upper Guinea.
  publication-title: Sci Rep.
  doi: 10.1038/srep21977
  contributor:
    fullname: E Fichet-Calvet
– volume: 7
  start-page: 694-700
  year: 2011
  ident: ref-131
  article-title: Argentine hemorrhagic fever vaccines.
  publication-title: Hum Vaccin.
  doi: 10.4161/hv.7.6.15198
  contributor:
    fullname: A Ambrosio
– volume: 13
  start-page: 2755-62
  year: 2017
  ident: ref-113
  article-title: Vaccines for epidemic infections and the role of CEPI.
  publication-title: Hum Vaccin Immunother.
  doi: 10.1080/21645515.2017.1306615
  contributor:
    fullname: S Plotkin
– volume: 12
  start-page: e0006971
  year: 2018
  ident: ref-69
  article-title: Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria.
  publication-title: PLoS Negl Trop Dis.
  doi: 10.1371/journal.pntd.0006971
  contributor:
    fullname: O Oloniniyi
– volume: 80
  start-page: 31-47
  year: 2018
  ident: ref-116
  article-title: Engineering DNA vaccines against infectious diseases.
  publication-title: Acta Biomater.
  doi: 10.1016/j.actbio.2018.08.033
  contributor:
    fullname: J Lee
– volume: 1
  start-page: 283-97
  year: 2001
  ident: ref-8
  article-title: Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals.
  publication-title: Vector Borne Zoonotic Dis.
  doi: 10.1089/15303660160025912
  contributor:
    fullname: A Demby
– volume: 3
  start-page: 11
  year: 2018
  ident: ref-77
  article-title: Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.
  publication-title: NPJ Vaccines.
  doi: 10.1038/s41541-018-0049-5
  contributor:
    fullname: H Hallam
– volume: 7
  start-page: 646-55
  year: 2016
  ident: ref-10
  article-title: Environmental-mechanistic modelling of the impact of global change on human zoonotic disease emergence: A case study of Lassa fever.
  publication-title: Methods Ecol Evol.
  doi: 10.1111/2041-210X.12549
  contributor:
    fullname: D Redding
– year: 2017
  ident: ref-94
  article-title: WHO Target Product Profile for Lassa virus Vaccine
– volume: 36
  start-page: 683-90
  year: 2018
  ident: ref-103
  article-title: Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2017.12.046
  contributor:
    fullname: M Wang
– start-page: 189-212
  year: 2018
  ident: ref-6
  article-title: Mice and Men: an Evolutionary History of Lassa Fever.
  publication-title: Biodivers Evol.
  doi: 10.1016/B978-1-78548-277-9.50011-5
  contributor:
    fullname: A Lalis
– volume: 351
  start-page: 16-9
  year: 2016
  ident: ref-104
  article-title: Unfilled Vials.
  publication-title: Science.
  doi: 10.1126/science.351.6268.16
  contributor:
    fullname: J Cohen
– volume: 17
  start-page: 195-207
  year: 2017
  ident: ref-54
  article-title: Immunobiology of Ebola and Lassa virus infections.
  publication-title: Nat Rev Immunol.
  doi: 10.1038/nri.2016.138
  contributor:
    fullname: J Prescott
– volume: 4
  start-page: 2031-48
  year: 2012
  ident: ref-76
  article-title: Pathogenesis of Lassa fever.
  publication-title: Viruses.
  doi: 10.3390/v4102031
  contributor:
    fullname: N Yun
– volume: 212 Suppl 2
  start-page: S443-51
  year: 2015
  ident: ref-126
  article-title: Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
  publication-title: J Infect Dis.
  doi: 10.1093/infdis/jiv316
  contributor:
    fullname: D Matassov
– volume: 215
  start-page: 1862-1872
  year: 2017
  ident: ref-78
  article-title: A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.
  publication-title: J Infect Dis.
  doi: 10.1093/infdis/jix201
  contributor:
    fullname: A McElroy
– volume: 171
  start-page: 179-88
  year: 1989
  ident: ref-109
  article-title: Protection of guinea pigs from lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of lassa virus.
  publication-title: Virology.
  doi: 10.1016/0042-6822(89)90525-4
  contributor:
    fullname: H Morrison
– volume: 6
  start-page: e1839
  year: 2012
  ident: ref-67
  article-title: Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation.
  publication-title: PLoS Negl Trop Dis.
  doi: 10.1371/journal.pntd.0001839
  contributor:
    fullname: D Asogun
– volume: 133
  start-page: 218-22
  year: 2016
  ident: ref-83
  article-title: Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2016.08.012
  contributor:
    fullname: R Cross
– volume: 55
  start-page: 661-6
  year: 1996
  ident: ref-70
  article-title: Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea.
  publication-title: Am J Trop Med Hyg.
  doi: 10.4269/ajtmh.1996.55.661
  contributor:
    fullname: J Ter Meulen
– volume: 9
  year: 2018
  ident: ref-73
  article-title: Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques.
  publication-title: mBio.
  doi: 10.1128/mBio.01896-18
  contributor:
    fullname: K Cashman
– volume: 314
  start-page: 20-6
  year: 1986
  ident: ref-25
  article-title: Lassa fever. Effective therapy with ribavirin.
  publication-title: N Engl J Med.
  doi: 10.1056/NEJM198601023140104
  contributor:
    fullname: J McCormick
– volume: 6
  start-page: 466-76
  year: 2000
  ident: ref-42
  article-title: Imported lassa fever in Germany: molecular characterization of a new lassa virus strain.
  publication-title: Emerging Infect Dis.
  doi: 10.3201/eid0605.000504
  contributor:
    fullname: S Günther
– volume: 92
  year: 2018
  ident: ref-99
  article-title: A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
  publication-title: J Virol.
  doi: 10.1128/JVI.02230-17
  contributor:
    fullname: X Carnec
– volume: 35
  start-page: 401-7
  year: 1986
  ident: ref-62
  article-title: Lassa virus hepatitis: a study of fatal Lassa fever in humans.
  publication-title: Am J Trop Med Hyg.
  doi: 10.4269/ajtmh.1986.35.401
  contributor:
    fullname: J McCormick
– volume: 25
  start-page: 4093-102
  year: 2007
  ident: ref-46
  article-title: A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2007.02.038
  contributor:
    fullname: R Carrion
– volume: 476
  start-page: 249-56
  year: 2015
  ident: ref-16
  article-title: Gairo virus, a novel arenavirus of the widespread Mastomys natalensis: Genetically divergent, but ecologically similar to Lassa and Morogoro viruses.
  publication-title: Virology.
  doi: 10.1016/j.virol.2014.12.011
  contributor:
    fullname: S Gryseels
– volume: 10
  start-page: e0122839
  year: 2015
  ident: ref-57
  article-title: Novel mechanism of arenavirus-induced liver pathology.
  publication-title: PLoS One.
  doi: 10.1371/journal.pone.0122839
  contributor:
    fullname: J Beier
– volume: 12
  start-page: 71-86
  year: 2013
  ident: ref-44
  article-title: The search for animal models for Lassa fever vaccine development.
  publication-title: Expert Rev Vaccines.
  doi: 10.1586/erv.12.139
  contributor:
    fullname: I Lukashevich
– volume: 111
  start-page: 276-88
  year: 2017
  ident: ref-11
  article-title: Understanding the cryptic nature of Lassa fever in West Africa.
  publication-title: Pathog Glob Health.
  doi: 10.1080/20477724.2017.1369643
  contributor:
    fullname: R Gibb
– year: 2018
  ident: ref-111
  article-title: Use of recombinant ML29 platform to generate polyvalent live-attenuated vaccines against lassa fever and other infectious diseases
  contributor:
    fullname: M Iwasaki
– volume: 155
  start-page: 456-64
  year: 1987
  ident: ref-27
  article-title: Clinical virology of Lassa fever in hospitalized patients.
  publication-title: J Infect Dis.
  doi: 10.1093/infdis/155.3.456
  contributor:
    fullname: K Johnson
– year: 2018
  ident: ref-34
  article-title: Lassa Fever
– volume: 79
  start-page: 374-9
  year: 1985
  ident: ref-51
  article-title: Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates.
  publication-title: Trans R Soc Trop Med Hyg.
  doi: 10.1016/0035-9203(85)90386-4
  contributor:
    fullname: P Jahrling
– volume: 180
  start-page: 3113-21
  year: 2008
  ident: ref-89
  article-title: Absence of CTL responses to early viral antigens facilitates viral persistence.
  publication-title: J Immunol.
  doi: 10.4049/jimmunol.180.5.3113
  contributor:
    fullname: A Schildknecht
– volume: 21
  start-page: 4137-50
  year: 2012
  ident: ref-19
  article-title: Complex patterns of host switching in New World arenaviruses.
  publication-title: Mol Ecol.
  doi: 10.1111/j.1365-294X.2012.05663.x
  contributor:
    fullname: N Irwin
– volume: 379
  start-page: 1745-53
  year: 2018
  ident: ref-68
  article-title: Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018.
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1804498
  contributor:
    fullname: K Siddle
– volume: 2
  start-page: e183
  year: 2005
  ident: ref-97
  article-title: Development of a new vaccine for the prevention of Lassa fever.
  publication-title: PLoS Med.
  doi: 10.1371/journal.pmed.0020183
  contributor:
    fullname: T Geisbert
– volume: 92
  start-page: e01190-17
  year: 2018
  ident: ref-128
  article-title: Single Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
  publication-title: J Virol.
  doi: 10.1128/JVI.01190-17
  contributor:
    fullname: D Matassov
– volume: 4
  start-page: 2766-85
  year: 2012
  ident: ref-130
  article-title: Immune responses and Lassa virus infection.
  publication-title: Viruses.
  doi: 10.3390/v4112766
  contributor:
    fullname: M Russier
– volume: 170
  start-page: 2797-801
  year: 2003
  ident: ref-61
  article-title: Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.
  publication-title: J Immunol.
  doi: 10.4049/jimmunol.170.6.2797
  contributor:
    fullname: S Mahanty
– volume: 359
  start-page: 1201-1202
  year: 2018
  ident: ref-31
  article-title: Nigeria hit by unprecedented Lassa fever outbreak.
  publication-title: Science.
  doi: 10.1126/science.359.6381.1201
  contributor:
    fullname: L Roberts
– volume: 29
  start-page: 1248-57
  year: 2011
  ident: ref-101
  article-title: Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2010.11.079
  contributor:
    fullname: X Jiang
– volume: 155
  start-page: 437-44
  year: 1987
  ident: ref-26
  article-title: A prospective study of the epidemiology and ecology of Lassa fever.
  publication-title: J Infect Dis.
  doi: 10.1093/infdis/155.3.437
  contributor:
    fullname: J McCormick
– volume: 16
  start-page: 663-666
  year: 2018
  ident: ref-29
  article-title: Lassa fever outbreaks in Nigeria.
  publication-title: Expert Rev Anti Infect Ther.
  doi: 10.1080/14787210.2018.1512856
  contributor:
    fullname: G Akpede
– volume: 106
  start-page: 3473-8
  year: 2009
  ident: ref-112
  article-title: Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest.
  publication-title: Proc Natl Acad Sci U S A.
  doi: 10.1073/pnas.0900088106
  contributor:
    fullname: S Emonet
– volume: 166
  start-page: 5-8
  year: 2016
  ident: ref-133
  article-title: Roots, Not Parachutes: Research Collaborations Combat Outbreaks.
  publication-title: Cell.
  doi: 10.1016/j.cell.2016.06.029
  contributor:
    fullname: N Yozwiak
– volume: 1
  start-page: 1399-402
  year: 1977
  ident: ref-58
  article-title: Lassa fever in Panguma Hospital, Sierra Leone, 1973-6.
  publication-title: Br Med J.
  doi: 10.1136/bmj.1.6073.1399
  contributor:
    fullname: E Keane
– volume: 155
  start-page: 445-55
  year: 1987
  ident: ref-59
  article-title: A Case-Control Study of the Clinical Diagnosis and Course of Lassa Fever.
  publication-title: J Infect Dis.
  doi: 10.1093/infdis/155.3.445
  contributor:
    fullname: J McCormick
– year: 2018
  ident: ref-115
  article-title: Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
– volume: 10
  start-page: 52
  year: 2013
  ident: ref-92
  article-title: An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.
  publication-title: Virol J.
  doi: 10.1186/1743-422X-10-52
  contributor:
    fullname: J Zapata
– volume: 160
  start-page: 1851-74
  year: 2015
  ident: ref-3
  article-title: Past, present, and future of arenavirus taxonomy.
  publication-title: Arch Virol.
  doi: 10.1007/s00705-015-2418-y
  contributor:
    fullname: S Radoshitzky
– volume: 13
  start-page: e1006073
  year: 2017
  ident: ref-12
  article-title: When Viruses Don't Go Viral: The Importance of Host Phylogeographic Structure in the Spatial Spread of Arenaviruses.
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1006073
  contributor:
    fullname: S Gryseels
– volume: 37
  start-page: 771-8
  year: 1982
  ident: ref-45
  article-title: Pathogenesis of Lassa virus infection in guinea pigs.
  publication-title: Infect Immun.
  doi: 10.1128/IAI.37.2.771-778.1982
  contributor:
    fullname: P Jahrling
– year: 2018
  ident: ref-129
  article-title: CEPI Awards Contract Worth Up To USD$19 million to Oxford University and Janssen Vaccines to Develop MERS, Lassa, and Nipah Vaccines
– volume: 22
  start-page: 694-7
  year: 2016
  ident: ref-17
  article-title: Arenavirus Diversity and Phylogeography of Mastomys natalensis Rodents, Nigeria.
  publication-title: Emerg Infect Dis.
  doi: 10.3201/eid2204.150155
  contributor:
    fullname: A Olayemi
– volume: 79
  start-page: 13934-42
  year: 2005
  ident: ref-87
  article-title: A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.
  publication-title: J Virol.
  doi: 10.1128/JVI.79.22.13934-13942.2005
  contributor:
    fullname: I Lukashevich
– volume: 75
  start-page: 11677-85
  year: 2001
  ident: ref-102
  article-title: Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
  publication-title: J Virol.
  doi: 10.1128/JVI.75.23.11677-11685.2001
  contributor:
    fullname: P Pushko
– volume: 9
  year: 2017
  ident: ref-123
  article-title: A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.
  publication-title: Sci Transl Med.
  doi: 10.1126/scitranslmed.aaj1701
  contributor:
    fullname: A Huttner
– volume: 17
  start-page: 1921-4
  year: 2011
  ident: ref-15
  article-title: Novel arenavirus, Zambia.
  publication-title: Emerg Infect Dis.
  doi: 10.3201/eid1710.10452
  contributor:
    fullname: A Ishii
– volume: 49
  start-page: 1157-61
  year: 2011
  ident: ref-37
  article-title: Current molecular epidemiology of Lassa virus in Nigeria.
  publication-title: J Clin Microbiol.
  doi: 10.1128/JCM.01891-10
  contributor:
    fullname: D Ehichioya
– year: 2018
  ident: ref-117
  article-title: Work on DNA Vaccines Still Has a Way to Go
  contributor:
    fullname: J Kelvey
– volume: 74
  start-page: 2186-92
  year: 2000
  ident: ref-81
  article-title: Characterization of human CD4+ T-Cell clones recognizing conserved and variable epitopes of the lassa virus nucleoprotein.
  publication-title: J Virol.
  doi: 10.1128/JVI.74.5.2186-2192.2000
  contributor:
    fullname: J ter Meulen
– volume: 15
  start-page: 1135-50
  year: 2016
  ident: ref-88
  article-title: Vaccine platforms to control Lassa fever.
  publication-title: Expert Rev Vaccines.
  doi: 10.1080/14760584.2016.1184575
  contributor:
    fullname: I Lukashevich
– volume: 327
  start-page: 1271-5
  year: 2003
  ident: ref-22
  article-title: Lassa fever: epidemiology, clinical features, and social consequences.
  publication-title: BMJ.
  doi: 10.1136/bmj.327.7426.1271
  contributor:
    fullname: J Richmond
– volume: 13
  start-page: 2902-11
  year: 2017
  ident: ref-110
  article-title: A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.
  publication-title: Hum Vaccin Immunother.
  doi: 10.1080/21645515.2017.1356500
  contributor:
    fullname: K Cashman
– volume: 26
  start-page: 5246-54
  year: 2008
  ident: ref-105
  article-title: Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.
  publication-title: Vaccine.
  doi: 10.1016/j.vaccine.2008.07.057
  contributor:
    fullname: I Lukashevich
– start-page: 177-195
  year: 1999
  ident: ref-80
  article-title: Lassa fever
  contributor:
    fullname: J McCormick
– volume: 11
  start-page: 416
  year: 2018
  ident: ref-18
  article-title: Widespread arenavirus occurrence and seroprevalence in small mammals, Nigeria.
  publication-title: Parasit Vectors.
  doi: 10.1186/s13071-018-2991-5
  contributor:
    fullname: A Olayemi
– volume: 74
  start-page: 6777-83
  year: 2000
  ident: ref-74
  article-title: Effective Vaccine for Lassa Fever.
  publication-title: J Virol.
  doi: 10.1128/JVI.74.15.6777-6783.2000
  contributor:
    fullname: S Fisher-Hoch
– volume: 21
  start-page: 609-18
  year: 2015
  ident: ref-41
  article-title: Sequence variability and geographic distribution of Lassa virus, Sierra Leone.
  publication-title: Emerging Infect Dis.
  doi: 10.3201/eid2104.141469
  contributor:
    fullname: T Leski
– volume: 389
  start-page: 505-18
  year: 2017
  ident: ref-119
  article-title: Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(16)32621-6
  contributor:
    fullname: A Henao-Restrepo
– volume: 15
  start-page: 519-27
  year: 2015
  ident: ref-114
  article-title: Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
  publication-title: Lancet Infect Dis.
  doi: 10.1016/S1473-3099(15)70043-5
  contributor:
    fullname: K Ramsauer
– volume: 88
  start-page: 6690-701
  year: 2014
  ident: ref-125
  article-title: Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.
  publication-title: J Virol.
  doi: 10.1128/JVI.03441-13
  contributor:
    fullname: D Clarke
SSID ssj0000993627
Score 2.303445
SecondaryResourceType review_article
Snippet Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis,...
Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, , which is widely...
Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis...
Lassa virus (LASV) is a highly prevalent mammarenavirus in West Africa and is maintained in nature in a persistently infected rodent host, Mastomys natalensis,...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
faculty1000
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 134
SubjectTerms Biodiversity
Candidates
Drug development
Fatalities
Fever
Food contamination & poisoning
Genetic diversity
Genomes
Infections
Lassa fever
Morbidity
Mortality
Pediatrics
Phylogenetics
Public health
Review
RNA polymerase
Severe acute respiratory syndrome
Tropical diseases
Vaccine development
Vaccines
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxUxEB-0B7GHYutHV1uJIHjadrPZzYeebG3pQb2oIIiEZJPQFtlK133Q_95Jsu_5VoRevG5CsslMkt8kM78BeCkq67lhXelatE0aakRpaofGiu8o6yL_B4-BwmefxMev8t1JpMlZpfqKPmGZHjhP3KFipubGI8pQoalMq4LkaCfjKcqkaZpsrVdyzZi6zLgHd-YYK12jAVjS5MaTwoNrjiZfiLfaE5vO-QGNSRQP6OxkSgT-m7AZTGTAuIn1_4VB_3alXDubTh_A1gQqyds8mG244_sduPdhejbfga2Up_LVQCavwYdw-R5BsyGLi-txIG7pm0FM70jwZnKZvSGIaMmYXTewffwvFMqPFFZFFqaLjZNvi3zjRugbknOW-OE1YSSRlS-8-_4IvpyefD4-K6e0C2XXIL4onWipDbIVIT5ZclsZGmKEK3PeWusrH4RniktWOce5E8xWAmdVCe8cswgfH8NGf9X7XSBWilBjeV13rjGCK2F556w0snOtpKGAw-WU65-ZXUNHqyQKSc-EpJOQNC3gKEpmVTuyY6cPqDN60hl9m84UwNbkqv_0cUvXe0v562mhDzql9MJiLgt4sSrGJRrfXUzvr8ZUJ8ao4-gLeJLVZfX_uMWKRrGmADFTpNkA5yX9xXmiAY9Mgko1T__HjDyD-4gEVb5b2oONX9ej34e7gxufp4X1G8xlI3s
  priority: 102
  providerName: Directory of Open Access Journals
Title Lassa virus diversity and feasibility for universal prophylactic vaccine [version 1; peer review: 3 approved]
URI http://dx.doi.org/10.12688/f1000research.16989.1
https://www.ncbi.nlm.nih.gov/pubmed/30774934
https://www.proquest.com/docview/2186998968
https://search.proquest.com/docview/2183185697
https://pubmed.ncbi.nlm.nih.gov/PMC6357994
https://doaj.org/article/93a26ae3269f40a59f8698797638a440
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6xPSB6qKC8AqUyEhKn3U3ixI8jlFZ7oAgJkLhZdmzTrdpstUsq9d8zdpxlg5CQuMbxc8bJN_bMNwBveG4c07SZ2hptk6rQfKpLi8aKawraBP4PFgKFF1_4p-_iw2mgyamHWJjotN-Y5ay9up61y4voW3lz3cwHP7H55_OTwKEmZTWfwASx4Y6JftlDHvwo8xQNXDK08Hw4xE7kORezIuRMnIUUMajfvJK0Gv2TInX_Pux7Hbgv7kLVv6HPP50od_5KZw_hIMFJ8q4f9iO459pDuH-eLswP4SBmqHy7Iclf8DEsPiJc1uR2ue42xA5eGUS3lnink7PsHUEsS7reaQPbx3GhOK5iQBW51U1o_Al8Ozv9erKYpnQK06ZC3DC1vC6MFzX34SqSmVwXPkSuUuuMMS53njsqmaC5tYxZTk3Ocfkkd9ZSg7DwKey1q9Y9B2IE9yWWl2VjK82Z5IY11ggtGluLwmcwHxZU3fSsGSpYG0EaaiQNFaWhigzeh3Xfvh1Yr-OD1fqHSrJXkuqSaYeIU_oq17X0AmtzRFRU6KrKM6A7UlO_-_hH10eDdFXawBsVU3VhMRMZvN4W49YL9ym6dasuvhNiz3H2GTzrlWE7_kG1MuAjNRlNcFyC2h7pvZN2v_jvmi_hAcI62R8UHcHez3XnXsFkY7vjeORwHDfML0llGLs
link.rule.ids 230,315,729,782,786,866,887,2108,4030,27934,27935,27936,53803,53805
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED6xIcH2MGDACAwwEhJPaZM4sZNHGJuKaCckhsSb5Z-saEunlkzaf8_ZSUqDkJD2movjOHeOv7PvvgN4yxNlmaQ6NgX6JnkqeSwzg86K1SnVnv-D-UThyVd--r38eOxpcoo-FyYE7Ws1H9UXl6N6fh5iK68u9biPExt_mR15DrWqysdbcBfna0I3nPSfLejB3zLv8oEzhj6e89vYHX3O-Sj1VRNHvkgMWjjPK5oPVqVA3r8Lu0569osb3_Rf-PPvMMqNdenkwS1H9BD2OiBK3rfiR3DH1vtwb9Ydte_DXqht-W5FukjDxzCZItCW5Hq-bFbE9PEcRNaGOCu7MNsbgiiYNG24Bz4fx4OKvAipWORaav_wJ_Dt5PjsaBJ3hRhinSPiiA0vUuXKgjt_iMlUIlPnc16psUopm1jHLa1YSRNjGDOcqoTjZ6-4NYYqBJRPYbte1PYZEFVyl6E8y7TJJWcVV0wbVcpSm6JMXQTjXhHiquXbEN5P8VoUAy2KoEWRRvDB62t9t-fLDhcWyx-i-8aiojJj0iJWrVyeyKJyJbbmiMVoKfM8iYBuaFv86eM_XR_2ViG6qb8SocgXilkZwZu1GCetP4mRtV004R6ftY6jj-CgNaL1-_cmGQEfmNdggEMJWlUgBu-s6PmtW76G-5Oz2VRMP51-fgE7CA6rdrvpELZ_LRv7ErZWpnkVpttvAUItXA
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RIlX0UKC8AgWChMRpNw8ndnyEtqtFtFUlQOJm2bHdLmqzq11Sqf-eseMsG4SEBNf4FWfG9jfxzDcAb1mqDJWkHukSbZMik2wkc43GiqkzUjv-D-oChaef2dm36ujY0eSsU315p_1azcbN1fW4mV1638rFdZ30fmLJ-emh41DjvEgW2iZbcBfXbFpuGOrfO-CDWzMLMcE5RTvPul_ZgULncpy5zIljlygGtZwVnBSDk8kT-O_CrpWOAePWNf0TBv3dlXLjbJrc_49ZPYC9AEjj912Vh3DHNPuwcxqu3Pdhz-e4fLeKg8fhI5ieIOCW8c1s2a5i3ft1xLLRsTUyuNvexoiG47Zz-8D-cU4o0CsfkhXfyNp1_hi-To6_HE5HISHDqC4QeYw0KzNlq5JZd5lJVSoz62JfiTZKKZMaywzhtCKp1pRqRlTK8NNzZrQmCoHlE9hu5o15BrGqmM2xPM9rXUhGOVO01qqSVa3LKrMRJL0wxKLj3RDOXnGSFANJCi9JkUXwwclsXdvxZvsH8-WFCN9ZcCJzKg1iVm6LVJbcVtiaISYjlSyKNAKyIXHxa4y_DH3Qa4YIW8BK-GRfWEyrCN6si3HxuhsZ2Zh56-u46HWcfQRPO0Vav3-vlhGwgYoNJjgsQc3yBOFBk57_c8vXsHN-NBEnH88-vYB7iBF599fpALZ_LFvzErZWun3lV9xPeKEv3A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lassa+virus+diversity+and+feasibility+for+universal+prophylactic+vaccine&rft.jtitle=F1000+research&rft.au=Lukashevich%2C+Igor+S&rft.au=Paessler+Slobodan&rft.au=de+la+Torre+Juan+Carlos&rft.date=2019&rft.pub=Faculty+of+1000+Ltd&rft.eissn=2046-1402&rft.volume=8&rft_id=info:doi/10.12688%2Ff1000research.16989.1&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2046-1402&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2046-1402&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2046-1402&client=summon